News

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set

Pfizer (NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and treatment. But the drop in demand for those products

With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been

The new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh stocks to consider adding to a portfolio. The types of stocks you gravitate toward will broadly be

Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the

COVID-19 has been especially rough for Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) investors over the last couple of years. Shares of both drugmakers have plunged as the demand for their

While the market bounced back last year, some stocks failed to keep pace with broader equities. That was the case with pharma giant AbbVie (NYSE: ABBV) and e-commerce specialist Etsy (NASDAQ: ETSY)

It's hard for me to pick my top favorite in many categories. Whether talking about actors, athletes, songs, singers, movies, or TV shows, I find it difficult to single one out as the best.

This

Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV) share a common past. About a decade ago, Abbott spun out its pharmaceuticals business into a separate company to create AbbVie. Since then

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

If you're in the process of rebalancing your portfolio, you might be considering buying Pfizer (NYSE: PFE) stock. After all, the drugmaker pays a sizzling 5.92% dividend yield, its shares trade at

Last year, pharmaceutical giant Pfizer (NYSE: PFE) encountered several issues, none more significant than the massive drop in revenue and earnings it experienced due to a shrinking coronavirus

There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY)

Last year wasn't a particularly good one for Pfizer (NYSE: PFE). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And

Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the

After a tough 2022 and gains in 2023, it's fair to say the stock market is probably on the way to better days. In any case, history tells us that bear markets, such as the one that began in 2022

There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among them. However, neither of these methods can

Pharmaceutical giant Pfizer (NYSE: PFE) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and

Pfizer (NYSE: PFE) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the

Pharmaceutical company AbbVie (NYSE: ABBV) has been a double-deal of price growth and dividend income over the past five years. It achieved 129% in total returns in that time, outpacing the S&P 500.

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered market-beating returns over the past 12 months, five years, and 10 years. Existing shareholders are happy, but those still on the

Income investors love high dividend yields. Unfortunately, those yields often come with unacceptable trade-offs in the form of significant risk and/or low overall growth prospects. That's not always

Investors seeking stocks that can produce dramatic gains in 2024 can find what they're looking for in the biopharmaceutical industry. Clinical-trial results that these two companies are expected to